Report initial results from the TRuE-AD Phase 3 program of ruxolitinib cream in atopic dermatitis

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 29 Oct 2019
Due: 30 Jun 2020
Delivered: April 2020

Deadline
Met
Late
Not met
Today

What the company said

“The Phase 3 TRuE-AD development program of ruxolitinib cream in patients with atopic dermatitis is ongoing, with initial results expected in the first half of 2020.”

SourceIncyte Form 8-K press release, 2019-10-29
FilingSEC filing index
Deadline as statedin the first half of 2020
Deadline used30 Jun 2020, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2019-INCY-005664
Cite as https://keptindex.org/c/KI-C-2019-INCY-005664/ — this address never changes.

What we found

Evidence strength A What the grades mean

Incyte presented safety and efficacy data from both TRuE-AD Phase 3 trials in April 2020, before the end of the first-half-2020 deadline, and both trials met their primary endpoints.

A
Incyte 10-Q filed 2020-08-04 Regulatory filing · published 4 Aug 2020 · retrieved 10 Oct 2026 · kept permanently by the SEC
“In April 2020, safety and efficacy data from the two Phase III trials in the TRuE-AD program evaluating ruxolitinib cream in mild-to-moderate atopic dermatitis were presented at the Revolutionizing Atopic Dermatitis (RAD) virtual symposium; both trials met their primary endpoints.” ✓ confirmed on the page

Market reaction: the shares moved -6.2% against the S&P 500 over the three sessions around the disclosure (3 Aug 2020 to 6 Aug 2020). What this measures

Checked 10 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +365 days
3 versions

Version 1 · original · stated 29 Oct 2019

Deadline 30 Jun 2020 (“in the first half of 2020”) · wording expected
Version 2 · stated 4 Aug 2020

Deadline 31 Dec 2021 (“in 2021”) · wording expected

“evaluating ruxolitinib cream in patients with vitiligo are proceeding as planned, with results expected in 2021.”
Source for this version
Version 3 · stated 4 May 2021

Deadline 30 Jun 2021 (“results expected in Q2'21”) · wording expected

“The two Phase 3 trials in the TRuE-V program are ongoing with results expected in Q2'21.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Report
Deliverable: TRuE-AD Phase 3 initial results
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Incyte? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.